Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

61.44 +1.41 (+2.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts
 
Via Benzinga
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
 
Via Benzinga
This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market
Kymera Therapeutics Q2 2025 earnings miss estimates with $11.48M revenue (-55% YoY) and $0.95 EPS loss. Stock drops 2.7% pre-market despite clinical progress in STAT6 candidate. 
Via Chartmill
Topics Earnings
Kymera Revenue Drops 55 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
What to Expect from Kymera Therapeutics's Earnings
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Kymera Therapeutics
 
Via Benzinga
What's Next: Kymera Therapeutics's Earnings Preview
 
Via Benzinga
Earnings Scheduled For August 11, 2025
 
Via Benzinga
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD. 
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock
 
Via Benzinga
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments. 
Via Stocktwits
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development. 
Via MarketBeat
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
 
Via Benzinga
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish
Morgan Stanley, BofA, and Citi upgraded the stock, citing strong safety, biomarker, and degradation data for its STAT6 degrader KT-621. 
Via Stocktwits
Here are the top movers in Monday's session.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026. 
Via Benzinga
These stocks that are showing activity before the opening bell on Monday.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Friday's after hours session: top gainers and losers
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts
 
Via Benzinga
Earnings Scheduled For May 9, 2025
 
Via Benzinga
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.